Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...

Shares of Regeneron Pharmaceuticals Inc. surged 11.82% to $654.48 Tuesday, on what proved to be an all-around positive ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to ...